丙泊酚相关高甘油三酯血症的发生率及危险因素分析
38例(27.9%)发生高甘油三酯血症,中位发生时间47小时;累积丙泊酚剂量是唯一显著的独立危险因素(OR 1.04,95%CI 1.01–1.08,P=0.016)。38例中2例(5.3%)诊断急性胰腺炎。提示丙泊酚累积剂量越高越应监测甘油三酯,但原文观察到相当数量患者在高甘油三酯下仍继续丙泊酚治疗。
要点
- 接受持续丙泊酚输注≥24小时的成人ICU患者中,27.9%(38/136)出现甘油三酯≥400 mg/dL,中位发生时间47小时。
- 累积丙泊酚剂量是高甘油三酯血症唯一独立危险因素(OR 1.04;95%CI 1.01–1.08;P=0.016)。
- 高甘油三酯血症患者中急性胰腺炎发生率为5.3%(2/38)。
- 原文指出尽管高甘油三酯血症发生率高,仍有相当数量患者继续丙泊酚治疗。
- 该研究为单中心病例对照设计,结论需前瞻性研究进一步验证(原文结论)。
适用人群与场景
- 排除:入院即诊断急性胰腺炎者,以及丙泊酚给药期间未检测任何血清甘油三酯水平者。
- 场景:三级学术医疗中心ICU,机械通气成人患者。
诊断标准与关键阈值
- 丙泊酚相关高甘油三酯血症定义:甘油三酯水平≥400 mg/dL。
- 高甘油三酯血症发生时间以中位时间47小时描述(原文未给出监测频率方案)。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 高甘油三酯血症患者中可出现急性胰腺炎:38例中2例(5.3%)被诊断急性胰腺炎,需警惕。
研究设计与关键结果
- 研究类型:单中心病例对照研究,单中心(Brigham and Women's Hospital,波士顿三级学术医疗中心)。
- 样本量:552例评估纳入,最终136例纳入分析。
- 主要结局:38例(27.9%)发生高甘油三酯血症,中位发生时间47小时。
- 危险因素:累积丙泊酚剂量为唯一显著独立危险因素(OR 1.04;95%CI 1.01–1.08;P=0.016),采用混合多因素logistic回归分析。
- 次要结局:38例高甘油三酯血症患者中2例(5.3%)诊断急性胰腺炎。
- 原文结论:尽管高甘油三酯血症发生率高,仍有相当数量患者继续丙泊酚治疗,胰腺炎患病率相对较低;需未来研究进一步验证。
证据类型、等级与局限
- 证据类型:单中心病例对照研究(原文设计)。
- 局限:单中心、观察性设计、样本量136例、仅纳入有甘油三酯检测的患者(原文排除未检测者),原文结论称未来需进一步分析验证。
对床旁实践的改变
- 对持续丙泊酚输注≥24小时的成人ICU患者,应关注甘油三酯水平,尤其累积剂量较高者(原文示累积剂量为独立危险因素)。
- 原文观察到高甘油三酯血症发生率高但相当数量患者仍继续丙泊酚治疗、胰腺炎患病率相对较低,提示临床决策需权衡,但原文未给出停药阈值或替代方案。
- 原文为单中心观察性研究,不能据此确立常规监测频率或停药指征。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The objective of this study was to describe the incidence of propofol-induced hypertriglyceridemia and the risk factors associated with hypertriglyceridemia in mechanically ventilated ICU patients while receiving propofol.
DESIGN: This was a single-center case-control study.
SETTING: Brigham and Women's Hospital, a tertiary academic medical center in Boston, MA.
SUBJECTS: Adult ICU patients who received continuous infusion propofol for at least 24 hours from May 1, 2019, to December 31, 2019, were included. Patients were excluded if they were diagnosed with acute pancreatitis upon admission or did not have any serum triglyceride levels evaluated during propofol administration.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The major outcome was the incidence and risk factors associated with the development of propofol-induced hypertriglyceridemia, defined as triglyceride level greater than or equal to 400 mg/dL. Minor outcomes included the prevalence of acute pancreatitis. A hybrid multivariate logistic regression analysis was used to evaluate the relation between individual risk factors and the dependent variable of hypertriglyceridemia. During the study period, 552 patients were evaluated for inclusion, of which 136 were included in the final analysis. A total of 38 patients (27.9%) developed hypertriglyceridemia with a median time to hypertriglyceridemia of 47 hours. The only significant independent risk factor for development of hypertriglyceridemia identified was the cumulative propofol dose (odds ratio, 1.04; 95% CI, 1.01-1.08; p = 0.016). Two of the 38 hypertriglyceridemia patients (5.3%) were diagnosed with acute pancreatitis.
CONCLUSIONS: In our analysis, approximately one third of patients developed hypertriglyceridemia with cumulative propofol dose identified as a significant predictor of the development of hypertriglyceridemia. Despite a high incidence of hypertriglyceridemia, a significant number of patients continued propofol therapy, and a relatively low prevalence of pancreatitis was observed. Future analyses are warranted to further investigate these results.
参考来源
- Corrado MJ, Kovacevic MP, Dube KM, et al. The Incidence of Propofol-Induced Hypertriglyceridemia and Identification of Associated Risk Factors. Crit Care Explor. 2020. PMID: 33274340. doi:10.1097/CCE.0000000000000282
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。